参考文献/References:
[1] Dugas V,Beauchamp C,Chabot-Roy G,et al.Implication of the CD47 pathway in autoimmune diabetes[J].J Autoimmun,2010,35(1):23-32.DOI:10.1016/j.jaut.2010.01.002.
[2] Ried JS,Jeff MJ,Chu AY,et al.A principal component meta-analysis on multiple anthropometric traits identifies novel loci for body shape[J].Nat Commun,2016,7:13357.DOI:10.1038/ncomms13357.
[3] Justice AE,Winkler TW, Feitosa MF,et al. Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits[J].Nat Commun,2017,8:14977.DOI:10.1038/ncomms14977.
[4] Wiewiora M,Piecuch J,Sedek L,et al.The effects of obesity on CD47 expression in erythrocytes[J].Cytometry B Clin Cytom,2017,92(6):485-491.DOI:10.1002/cyto.b.21232.
[5] Maimaitiyiming H,Norman H,Zhou Q,et al.CD47 deficiency protects mice from diet-induced obesity and improves whole body glucose tolerance and insulin sensitivity[J].Sci Rep,2015,5:8846.DOI:10.1038/srep08846.
[6] Barclay AN,Van den Berg TK.The interaction between signal regulatory protein alpha(SIRPα)and CD47: structure, function, and therapeutic target[J].Annu Rev Immunol,2014,32:25-50.DOI:10.1146/annurev-immunol-032713-120142.
[7] Per-Arne O.Role of CD47 and signal regulatory protein alpha(SIRPα)in regulating the clearance of viable or aged blood cells[J].Transfus Med Hemother,2012,39(5):315-320.DOI:10.1159/000342537.
[8] Rogers NM,Yao M,Novelli EM,et al.Activated CD47 regulates multiple vascular and stress responses:implications for acute kidney injury and its management[J].Am J Physiol Renal Physiol,2012,303(8):F1117-F1125.DOI:10.1152/ajprenal.00359.2012.
[9] Soto-Pantoja DR,Kaur S,Roberts DD.CD47 signaling pathways controlling cellular differentiation and responses to stress[J].Crit Rev Biochem Mol Biol,2015,50(3):212-230.DOI:10.3109/10409238.2015.1014024.
[10] Roberts DD,Kaur S,Isenberg JS.Regulation of cellular redox signaling by matricellular proteins in vascular biology, immunology, and cancer[J].Antioxid Redox Signal,2017,27(12):874-911.DOI:10.1089/ars.2017.7140.
[11] Murphy-Ullrich JE,Suto MJ.Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease[J].Matrix Biol,2017,pii: S0945-053X(17)30359-1.DOI:10.1016/j.matbio.2017.12.009.
[12] Holm CK,Engman S,Sulniute R,et al.Lack of SIRPα phosphorylation and concomitantly reduced SHP-2-PI3K-Akt2 signaling decrease osteoblast differentiation[J].Biochem Biophys Res Commun,2016,478(1):268-273.DOI:10.1016/j.bbrc.2016.07.048.
[13] Koh E,Lee EJ,Nam GH,et al.Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis[J].Biomaterials,2017,121:121-129.DOI:10.1016/j.biomaterials.2017.01.004.
[14] Weiskopf K.Cancer immunotherapy targeting the CD47/SIRPα axis[J].Eur J Cancer,2017,76:100-109.DOI:10.1016/j.ejca.2017.02.013.
[15] Dai H,Friday AJ,Abou-Daya KI,et al.Donor SIRPα polymorphism modulates the innate immune response to allogeneic grafts[J].Sci Immunol,2017,2(12).pii: eaam6202.DOI:10.1126/sciimmunol.aam6202.
[16] Matsuo Y,Tanaka M,Yamakage H,et al.Thrombospondin 1 as a novel biological marker of obesity and metabolic syndrome[J].Metabolism,2015,64(11):1490-1499.DOI:10.1016/j.metabol.2015.07.016.
[17] Kong P,Cavalera M,Frangogiannis NG,et al.The role of thrombospondin(TSP)-1 in obesity and diabetes[J].Adipocyte,2014,3(1):81-84.DOI:10.4161/adip.26990.
[18] Kong P,Gonzalez-Quesada C,Li N,et al.Thrombospondin-1 regulates adiposity and metabolic dysfunction in diet-induced obesity enhancing adipose inflammation and stimulating adipocyte proliferation[J].Am J Physiol Endocrinol Metab,2013,305(3):E439-E450.DOI:10.1152/ajpendo.00006.2013.
[19] Matsugi K,Hosooka T,Nomura K,et al.Thrombospondin 1 suppresses insulin signaling in C2C12 myotubes[J].Kobe J Med Sci,2016,62(1):E13-E18.
[20] Thivolet C,Vial G,Cassel R,et al.Reduction of endoplasmic reticulum-mitochondria interactions in beta cells from patients with type 2 diabetes[J].PLoS One,2017,12(7):e0182027.DOI:10.1371/journal.pone.0182027.
[21] Cunha DA,Cito M,Carlsson PO,et al.Thrombospondin 1 protects pancreatic β-cells from lipotoxicity via the PERK-NRF2 pathway[J].Cell Death Differ,2016,23(12):1995-2006.DOI:10.1038/cdd.2016.89.
[22] Barrett JC,Clayton DG,Concannon P,et al.Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes[J].Nat Genet,2009,41(6):703-707.DOI:10.1038/ng.381.
[23] Wong AS,Mortin-Toth S,Sung M,et al.Polymorphism in the innate immune receptor SIRPα controls CD47 binding and autoimmunity in the nonobese diabetic mouse[J].J Immunol,2014,193(10):4833-4844. DOI:10.4049/jimmunol.1401984.
[24] Kobayashi M,Ohnishi H,Okazawa H,et al.Expression of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 in pancreatic beta-cells and its role in promotion of insulin secretion and protection against diabetes[J].Endocrinology,2008,149(11):5662-5669.DOI:10.1210/en.2008-0236.
[25] Kojima Y,Volkmer JP,McKenna K,et al.CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis[J].Nature,2016,536(7614):86-90.DOI:10.1038/nature18935.